Distinguished in Pulmonary Fibrosis

Dr. Zeenat Safdar

Pulmonary Medicine
Tmh Physician Associates PLLC
6565 Fannin St, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Distinguished in Pulmonary Fibrosis
Tmh Physician Associates PLLC
6565 Fannin St, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Zeenat Safdar is a Pulmonary Medicine provider in Houston, Texas. Dr. Safdar is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Fibrosis. Her top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Pulmonary Fibrosis, Acute Interstitial Pneumonia, and Lung Transplant. Dr. Safdar is currently accepting new patients.

Her clinical research consists of co-authoring 51 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 6 articles and participated in 1 clinical trial in the study of Pulmonary Fibrosis.

Specialties
Pulmonary Medicine
Licenses
Internal Medicine in TX
Hospital Affiliations
Houston Methodist Hospital
Houston Methodist Baytown Hospital
Houston Methodist The Woodlands Hospital
Houston Methodist Sugarland Hospital
Houston Methodist Willowbrook Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

TMH PHYSICIAN ASSOCIATES PLLC
6565 Fannin St, Houston, TX 77030
Other Locations
TMH PHYSICIAN ASSOCIATES PLLC
7575 San Felipe St, Suite 155, Houston, TX 77063
TMH PHYSICIAN ASSOCIATES PLLC
16605 Sw Fwy 410, Methodist Diag Card Of Hou, Sugar Land, TX 77479
TMH PHYSICIAN ASSOCIATES PLLC
4710 Bellaire Blvd, Bellaire, TX 77401
TMH PHYSICIAN ASSOCIATES PLLC
6445 Main St, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
Enrollment Status: Recruiting
Publish Date: October 14, 2025
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Biological
Study Drug: Sotatercept
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Completed
Publish Date: April 19, 2023
Intervention Type: Drug, Other
Study Drug: Sotatercept
Study Phase: Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

51 Total Publications

Clinical impact of idiopathic pulmonary fibrosis on SARS-CoV-2 patient outcomes: a comprehensive analysis in the pre-vaccination era.
Clinical impact of idiopathic pulmonary fibrosis on SARS-CoV-2 patient outcomes: a comprehensive analysis in the pre-vaccination era.
Journal: Frontiers in medicine
Published: January 26, 2025
Similar Doctors
Elite in Pulmonary Fibrosis
Dr. Ivan O. Rosas
Pulmonary Medicine | Intensive Care Medicine
Elite in Pulmonary Fibrosis
Dr. Ivan O. Rosas
Pulmonary Medicine | Intensive Care Medicine

Baylor College Of Medicine

6720 Bertner Ave, 
Houston, TX 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ivan Rosas is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Houston, Texas. Dr. Rosas is rated as an Elite provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Pulmonary Fibrosis, Acute Interstitial Pneumonia, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, and Lung Transplant. Dr. Rosas is currently accepting new patients.

Distinguished in Pulmonary Fibrosis
Dr. Howard J. Huang
Pulmonary Medicine
Distinguished in Pulmonary Fibrosis
Dr. Howard J. Huang
Pulmonary Medicine

Tmh Physician Associates PLLC

6565 Fannin St, 
Houston, TX 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Howard Huang is a Pulmonary Medicine provider in Houston, Texas. Dr. Huang is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Idiopathic Pulmonary Fibrosis, Acute Interstitial Pneumonia, COVID-19, Lung Transplant, and Gastrostomy. Dr. Huang is currently accepting new patients in some locations.

Distinguished in Pulmonary Fibrosis
Dr. Clinton H. Doerr
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine
Distinguished in Pulmonary Fibrosis
Dr. Clinton H. Doerr
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine

Pulmonary Critical Care And Sleep Medicine Consultants, Llp

6560 Fannin St, Suite 1632, 
Houston, TX 
 (0.1 miles away)
713-255-4000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Clinton Doerr is a Pulmonary Medicine specialist and a Sleep Medicine provider in Houston, Texas. Dr. Doerr is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Lung Metastases, Bronchiectasis, Pneumonia, and Pulmonary Fibrosis. Dr. Doerr is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Safdar's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile